Forest Aerobid Market Share Is Stable At 10%-10.5%, Firm Reports
Executive Summary
Forest's share of the inhaled steroid market with Aerobid (flunisolide) has stabilized at 10%-10.5%, CFO Kenneth Goodman told the Bear Stearns health care conference in New York City Sept. 23.